The overall Specific Aim of the Career Development Program (CDP) is to recruit and develop the careers of junior faculty members who are committed to translational research in prostate cancer, and, in well-justified cases, mid-level and senior investigators who are already established in another area of research who want to redirect their research focus to the field of prostate cancer. The future of prostate cancer research lies in the continued entry of creative and innovative investigators into the field and the development of basic and translational projects that solve areas of unmet need. Institutional support of these endeavors is also critical to advances in the field;therefore the Prostate SPORE's CDP is supplemented by institutional funds to allow for rapid funding of important new initiatives within the scope of our SPORE research goals. Institutional funding totaling $675,000 annually has been secured for SPORE project and core support, as well as to provide supplemental funds for the CDP budget, allowing for the SPORE program to support promising new investigators working in the field of prostate cancer translational research. The priority for funding will be those applicants with potential for an independent research career in the field of prostate cancer, and whose initiatives are considered of highest scientific merit and with translational potential and relevance to the overall research mission of the UCLA Prostate SPORE. After initial review by the CDP Selection Committee, the Executive Committee approves the funding line and determines priorities for use of the CDP funds. Annual funding for each project will be a minimum of $50,000, and a minimum of two CDP awards will be funded annually.

Public Health Relevance

Prostate cancer is the most common cancer diagnosis and the second leading cause of cancer-related death in American men. The CDP plays a key role in recruiting and training exceptional scientific talent for translational research projects in prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092131-12
Application #
8760367
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$205,118
Indirect Cost
$75,312
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Tan, Nelly; Shen, Luyao; Khoshnoodi, Pooria et al. (2018) Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. J Urol 199:1218-1223
Donin, Nicholas M; Reiter, Robert E (2018) Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med 59:177-182
Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496
Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82
Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482
Mitra, Mithun; Lee, Ha Neul; Coller, Hilary A (2018) Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts. J Vis Exp :
Zou, Yongkang; Qi, Zhi; Guo, Weilong et al. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439. Mol Cancer Ther 17:2091-2099

Showing the most recent 10 out of 339 publications